Indaptus Corp - נכסים נקיים למניה בודדת INDP

Investments in Indaptus Therapeutics (INDP) research and development remain independent of market cycles and inflationary shocks. The net asset value per common share reflects current capital, where the 0.09 metric serves as the target level. Future revenue is based on the implementation of cancer immunotherapy. The company currently relies on unique bacterial vectors under strict FDA supervision, awaiting drug approval to begin commercialization.

Indaptus Therapeutics (INDP) is advancing high-risk developments in the field of immuno-oncology, where business sustainability depends directly on liquidity availability. This metric is calculated as the difference between all assets and liabilities divided by the number of shares, allowing the net asset value per common share to assess the real value of capital and the risk of resource impairment during the platform's early stages.